{"id":"aprepitant-palonosetron-dexamethasone","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Hiccups"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL1189679","moleculeType":"Small molecule","molecularWeight":"296.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aprepitant is a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center. Palonosetron is a 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone. Dexamethasone is a corticosteroid that provides additional antiemetic effects through multiple mechanisms including glucocorticoid receptor activation. Together, these agents provide comprehensive CINV prophylaxis across acute, delayed, and breakthrough phases.","oneSentence":"This combination blocks chemotherapy-induced nausea and vomiting (CINV) through three complementary pathways: NK1 receptor antagonism, 5-HT3 receptor antagonism, and glucocorticoid anti-inflammatory effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:51.619Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy"}]},"trialDetails":[{"nctId":"NCT06952920","phase":"PHASE3","title":"Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2025-08-21","conditions":"Standard Quadruple Antiemetic Therapy, Electroacupuncture, Chemotherapy-induced Gastrointestinal Symptom Cluster","enrollment":388},{"nctId":"NCT07081256","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-01-03","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":665},{"nctId":"NCT03578081","phase":"PHASE3","title":"Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2018-11-20","conditions":"Malignant Neoplasm","enrollment":690},{"nctId":"NCT06200168","phase":"PHASE3","title":"Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2024-01-16","conditions":"Electroacupuncture, Olanzapine-contained Four-drug Antiemetic, Nausea and Vomiting","enrollment":370},{"nctId":"NCT05773950","phase":"NA","title":"Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention","status":"ENROLLING_BY_INVITATION","sponsor":"Samsung Medical Center","startDate":"2023-08-18","conditions":"Postoperative Nausea and Vomiting, Gynecologic Surgical Procedures, Laparoscopy","enrollment":144},{"nctId":"NCT02116530","phase":"PHASE3","title":"Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2014-08-20","conditions":"Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":401},{"nctId":"NCT01843868","phase":"NA","title":"Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP","status":"WITHDRAWN","sponsor":"Australasian Leukaemia and Lymphoma Group","startDate":"2012-01","conditions":"Lymphoma, Non-Hodgkin","enrollment":""},{"nctId":"NCT05509634","phase":"PHASE3","title":"Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors","status":"COMPLETED","sponsor":"Fujian Shengdi Pharmaceutical Co., Ltd.","startDate":"2022-09-21","conditions":"Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy","enrollment":754},{"nctId":"NCT03674294","phase":"PHASE3","title":"Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-08-04","conditions":"Gastrointestinal Neoplasms, Chemotherapy-induced Nausea and Vomiting","enrollment":248},{"nctId":"NCT04437017","phase":"PHASE3","title":"Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV","status":"COMPLETED","sponsor":"Fifth Affiliated Hospital, Sun Yat-Sen University","startDate":"2020-02-03","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":557},{"nctId":"NCT04912271","phase":"PHASE3","title":"Granisetron Transdermal Patch for Prophylaxis of Delayed CINV","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-06-10","conditions":"Chemotherapy-induced Nausea and Vomiting (CINV)","enrollment":140},{"nctId":"NCT02625181","phase":"NA","title":"Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2016-07","conditions":"Postoperative Nausea and Vomiting","enrollment":27034},{"nctId":"NCT03831633","phase":"PHASE4","title":"Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients","status":"UNKNOWN","sponsor":"VIFORFRANCE","startDate":"2018-09-19","conditions":"Oncology","enrollment":426},{"nctId":"NCT02532634","phase":"PHASE4","title":"Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone","status":"COMPLETED","sponsor":"Kangdong Sacred Heart Hospital","startDate":"2015-08-19","conditions":"Cancer, Tumors","enrollment":292},{"nctId":"NCT01523457","phase":"PHASE2","title":"Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2011-10","conditions":"Metastatic Pancreatic Cancer, Pancreatic Cancer","enrollment":75},{"nctId":"NCT00381862","phase":"PHASE2","title":"Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-06","conditions":"Colorectal Cancer, Nausea and Vomiting","enrollment":54},{"nctId":"NCT00895245","phase":"PHASE2","title":"Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy","status":"TERMINATED","sponsor":"University of Washington","startDate":"2009-02","conditions":"Nausea and Vomiting, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx","enrollment":6},{"nctId":"NCT02484911","phase":"PHASE3","title":"Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting","status":"COMPLETED","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2015-05","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":120},{"nctId":"NCT00600353","phase":"PHASE2","title":"Multi-day Doses in Prevention of Nausea and Emesis","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2007-10","conditions":"Myeloma, Plasma-Cell, Lymphoma, Malignant","enrollment":20},{"nctId":"NCT02933099","phase":"PHASE3","title":"Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2016-10","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":300},{"nctId":"NCT02445872","phase":"PHASE2","title":"Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2015-12","conditions":"Chemotherapy-Induced Nausea and Vomiting, Lung Cancer","enrollment":80},{"nctId":"NCT00475085","phase":"PHASE3","title":"Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial","status":"COMPLETED","sponsor":"Joseph Roscoe","startDate":"2006-12","conditions":"Nausea","enrollment":1021},{"nctId":"NCT01111942","phase":"EARLY_PHASE1","title":"A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer","status":"TERMINATED","sponsor":"Southern Illinois University","startDate":"2010-02","conditions":"Head and Neck Cancer","enrollment":4},{"nctId":"NCT02431286","phase":"PHASE4","title":"Palonosetron Associated to Aprepitant in Prophylaxis of PONV","status":"UNKNOWN","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2014-10","conditions":"Postoperative Nausea and Vomiting","enrollment":90},{"nctId":"NCT01074697","phase":"PHASE3","title":"Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2010-04","conditions":"Nausea, Vomiting, Genital Neoplasms, Female","enrollment":246},{"nctId":"NCT01376297","phase":"PHASE3","title":"A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2011-07","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":413},{"nctId":"NCT01640340","phase":"NA","title":"Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2011-01","conditions":"Malignant Neoplasm","enrollment":40},{"nctId":"NCT01088022","phase":"PHASE3","title":"Aprepitant for Prevention of Acute and Delayed Nausea and Vomiting in Patients Receiving a High-emetogenic Dose of Cyclophosphamide for Peripheral Blood Stem Cells Harvesting","status":"UNKNOWN","sponsor":"Azienda Ospedaliera di Perugia","startDate":"2010-04","conditions":"Nausea, Vomiting","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PDA"],"phase":"phase_3","status":"active","brandName":"Aprepitant+palonosetron+dexamethasone","genericName":"Aprepitant+palonosetron+dexamethasone","companyName":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","companyId":"union-hospital-tongji-medical-college-huazhong-university-of-science-and-technol","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination blocks chemotherapy-induced nausea and vomiting (CINV) through three complementary pathways: NK1 receptor antagonism, 5-HT3 receptor antagonism, and glucocorticoid anti-inflammatory effects. Used for Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}